The DOI matches its Crossref record; 27 of the 32 references it cites were found in a registry or an index.
Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease
Open accessAbstract
Importance: Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the most common chronic liver disease worldwide. It is important to develop noninvasive tests to assess the disease severity and prognosis. Objective: To study the prognostic implications of baseline levels and dynamic changes of the vibration-controlled transient elastography (VCTE)-based scores developed for the diagnosis of advanced fibrosis (Agile 3+) and cirrhosis (Agile 4) in patients with MASLD. Design, Setting, and Participants: This cohort study included data from a natural history cohort of patients with MASLD who underwent VCTE examination at 16 tertiary referral centers in the US, Europe, and Asia from February 2004 to January 2023, of which the data were collected prospectively at 14 centers. Eligible patients were adults aged at least 18 years with hepatic steatosis diagnosed by histologic methods (steatosis in ≥5% of hepatocytes) or imaging studies (ultrasonography, computed tomography or magnetic resonance imaging, or controlled attenuation parameter ≥248 dB/m by VCTE). Main Outcomes and Measures: The primary outcome was liver-related events (LREs), defined as hepatocellular carcinoma or hepatic decompensation (ascites, variceal hemorrhage, hepatic encephalopathy, or hepatorenal syndrome), liver transplant, and liver-related deaths. The Agile scores were compared with histologic and 8 other noninvasive tests. Results: A total of 16 603 patients underwent VCTE examination at baseline (mean [SD] age, 52.5 [13.7] years; 9600 [57.8%] were male). At a median follow-up of 51.7 (IQR, 25.2-85.2) months, 316 patients (1.9%) developed LREs. Both Agile 3+ and Agile 4 scores classified fewer patients between the low and high cutoffs than most fibrosis scores and achieved the highest discriminatory power in predicting LREs (integrated area under the time-dependent receiver-operating characteristic curve, 0.89). A total of 10 920 patients (65.8%) had repeated VCTE examination at a median interval of 15 (IQR, 11.3-27.7) months and were included in the serial analysis. A total of 81.9% of patients (7208 of 8810) had stable Agile 3+ scores and 92.6% of patients (8163 of 8810) had stable Agile 4 scores (same risk categories at both assessments). The incidence of LREs was 0.6 per 1000 person-years in patients with persistently low Agile 3+ scores and 30.1 per 1000 person-years in patients with persistently high Agile 3+ scores. In patients with high Agile 3+ score at baseline, a decrease in the score by more than 20% was associated with substantial reduction in the risk of LREs. A similar trend was observed for the Agile 4 score, although it missed more LREs in the low-risk group. Conclusions and Relevance: Findings of this study suggest that single or serial Agile scores are highly accurate in predicting LREs in patients with MASLD, making them suitable alternatives to liver biopsy in routine clinical practice and in phase 2b and 3 clinical trials for steatohepatitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In longitudinal studies with serial VCTE measurements, changes in LSM (20% increase, stable, 20% decrease) correlated with the risk of liver-related events (including HCC) and liver-related death. 184,185”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [184]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several observational studies showed that LSM had good accuracy for liver-related events, liver-related and overall mortality. 178,183,184”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [184]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Baveno VII – Renewing consensus in portal hypertension
de Franchis, R., Bosch, J., Garcia-Tsao, G., Reiberger, T., Ripoll, C., Abraldes, J. G., Albillos, A., Baiges, A., Bajaj, J., Bañares, R., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.022 · Cited by 2,930
Self-citationNon-alcoholic fatty liver disease
Powell, E. E., Wong, V. W.-S., & Rinella, M. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32511-3 · Cited by 2,789
Self-citationTaylor, R. S., Taylor, R. J., Bayliss, S., Hagström, H., Nasr, P., Schattenberg, J. M., Ishigami, M., Toyoda, H., Wai-Sun Wong, V., Peleg, N., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.043 · Cited by 1,069
Self-citationHagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067
Self-citationAge as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis
McPherson, S., Hardy, T., Dufour, J.-F., Petta, S., Romero-Gomez, M., Allison, M., Oliveira, C. P., Francque, S., Van Gaal, L., Schattenberg, J. M., et al. (2017) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.453 · Cited by 945
Self-citationNewsome, P. N., Sasso, M., Deeks, J. J., Paredes, A. H., Boursier, J., Chan, W., Yilmaz, Y. N., Czernichow, S., Zheng, M., Wong, V. W., et al. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30383-8 · Cited by 839
Self-citationChanging epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Self-citationMittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.019 · Cited by 648
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise
Wong, V. W., Adams, L. A., de Lédinghen, V., Wong, G. L., & Sookoian, S. C. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0014-9 · Cited by 617
Self-citation
Research works printed but not linked: 5
- Blanche, 2013, Estimating and comparing time-dependent areas under receiver operating characteristic curves for censored event times with competing risks., Stat Med, 32, 5381, 10.1002/sim.5958 · DOI
- Yuan, 2018, A threshold-free summary index of prediction accuracy for censored time to event data., Stat Med, 37, 1671, 10.1002/sim.7606 · DOI
- Pencina, 2011, Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers., Stat Med, 30, 11, 10.1002/sim.4085 · DOI
- Uno, 2013, A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data., Stat Med, 32, 2430, 10.1002/sim.5647 · DOI
- Chow, 2019, Repeating measurements by transient elastography in non-alcoholic fatty liver disease patients with high liver stiffness., J Gastroenterol Hepatol, 34, 241, 10.1111/jgh.14311 · DOI · Paper page
Cited by
Sorted by citations
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Self-citationPhase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2413258 · Cited by 1,115
Self-citation(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Israelsen, M. E., Francque, S., Tsochatzis, E. A., & Krag, A. A. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01811-7 · Cited by 381
Self-citationCusi, K. J., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 417
Self-citationNatural history and progression of metabolic dysfunction-associated steatotic liver disease
Hagström, H., Shang, Y., Hegmar, H., & Nasr, P. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00193-6 · Cited by 310
Self-citationMetabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki‐Järvinen, H., & Loomba, R. S. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 365
Self-citationMetabolic Dysfunction–Associated Steatotic Liver Disease in Adults
Tilg, H., Petta, S., Stefan, N., & Targher, G. (2025) · JAMA · doi:10.1001/jama.2025.19615 · Cited by 309
Self-citationChan, S. L., Sun, H., Xu, Y., Zeng, H., El‐Serag, H. B., Lee, J. M., Schwartz, M., Finn, R. S., Seong, J., Wang, X. W., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01042-6 · Cited by 262
Self-citationEslam, M., Fan, J., Yu, M., Wong, V. W., Cua, I. H., Liu, C., Tanwandee, T., Gani, R. A., Seto, W., Alam, S., et al. (2025) · Hepatology International · doi:10.1007/s12072-024-10774-3 · Cited by 200
Self-citationThe first MASH drug therapy on the horizon: Current perspectives of resmetirom
Petta, S., Targher, G., Romeo, S., Pajvani, U. B., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2024) · Liver International · doi:10.1111/liv.15930 · Cited by 182
Self-citationNoureddin, M., Charlton, M., Harrison, S. A., Bansal, M. B., Alkhouri, N., Loomba, R. S., Sanyal, A. J., & Rinella, M. E. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.003 · Cited by 170
Self-citationEfruxifermin in Compensated Liver Cirrhosis Caused by MASH
Noureddin, M., Rinella, M. E., Chalasani, N., Neff, G. W., Lucas, K. J., Rodriguez, M. E., Rudraraju, M., Patil, R., Behling, C. A., Burch, M., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2502242 · Cited by 144
Bansal, M. B., Patton, H. M., Morgan, T. R. M., Carr, R. M., Dranoff, J. A., & Allen, A. M. (2025) · Hepatology · doi:10.1097/hep.0000000000001608 · Cited by 139
Noninvasive Assessment of Liver Fibrosis
Castéra, L., Rinella, M. E., & Tsochatzis, E. A. (2025) · New England Journal of Medicine · doi:10.1056/nejmra2403308 · Cited by 120
Self-citationByrne, C. D., Armandi, A., Pellegrinelli, V., Vidal‐Puig, A., & Bugianesi, E. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01045-z · Cited by 113
Self-citationZhou, X., Kim, S. U., Yip, T. C., Petta, S., Nakajima, A., Tsochatzis, E. A., Boursier, J., Bugianesi, E., Hagström, H., Chan, W., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-333074 · Cited by 94
Self-citationFan, J., Xu, X., Yang, R.-X., Nan, Y., Wei, L., Jia, J., Zhuang, H., Shi, J., Li, X., Cm, S., et al. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00311 · Cited by 92
Self-citationTherapeutic horizons in metabolic dysfunction–associated steatohepatitis
Newsome, P. N., & Loomba, R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186425 · Cited by 82
Self-citationYip, T. C., Lee, H. W., Lin, H., Tsochatzis, E. A., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M., Hagström, H., Boursier, J., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.014 · Cited by 63
Self-citationZhou, X., Lian, L., Chen, Q., Kim, S. U., Yip, T. C., Petta, S., Nakajima, A., Tsochatzis, E. A., Shi, J., Chan, W., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.08.017 · Cited by 54
Self-citationGries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 59
Liver biopsy evaluation in MASH drug development: Think thrice, act wise
Harrison, S. A., & Dubourg, J. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.06.008 · Cited by 45
Self-citationArmandi, A., Rosso, C., Caviglia, G. P., & Bugianesi, E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156080 · Cited by 47
Self-citationMetALD: Clinical aspects, pathophysiology and treatment
Gratacós‐Ginès, J., Ariño, S., Sancho‐Bru, P., Bataller, R. A., & Pose, E. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101250 · Cited by 45
Suresh, M. G., Mohamed, S., Geetha, H. S., Prabhu, S., Trivedi, N., Mehta, P. D., Damodaran, U. K., Brar, A., Sohal, A., Hatwal, J., et al. (2025) · Korean Circulation Journal · doi:10.4070/kcj.2025.0212 · Cited by 47
Impact of PNPLA3 I148M on Clinical Outcomes in Patients With MASLD
Petta, S., Armandi, A., & Bugianesi, E. (2024) · Liver International · doi:10.1111/liv.16133 · Cited by 38
Self-citationLiu, W., Huang, S., Ji, H., Kim, S. U., Yip, T. C., Wong, G. L., Petta, S., Tsochatzis, E. A., Nakajima, A., Bugianesi, E., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.02.034 · Cited by 38
Self-citationZhou, X., Li, Y., Kim, S. U., Yip, T. C., Petta, S., Nakajima, A., Tsochatzis, E. A., Shi, J., Chan, W., Boursier, J., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.07.011 · Cited by 36
Self-citationAgile scores in MASLD and ALD: External validation and their utility in clinical algorithms
Papatheodoridi, Μ., de Lédinghen, V., Lupșor‐Platon, M., Bronte, F., Boursier, J., Elshaarawy, O., Marra, F., Thiele, M. S., Markakis, G., Payancé, A., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.05.021 · Cited by 35
Self-citationStefanakis, K., Mingrone, G., George, J., & Mantzoros, C. S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156082 · Cited by 36
Huang, D. Q., Wilson, L., Behling, C. A., Amangurbanova, M., Kleiner, D. E., Kowdley, K. V., Dasarathy, S., Terrault, N. A., Diehl, A. M., Chalasani, N., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001015 · Cited by 39
Self-citationMetALD : New Perspectives on an Old Overlooked Disease
Ayares, G., Díaz, L. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Bataller, R. A., Loomba, R. S., Arab, J. P., & Arrese, M. A. (2025) · Liver International · doi:10.1111/liv.70017 · Cited by 34
Wang, Y., Song, S. J., Jiang, Y., Lai, J. C., Wong, G. L., Wong, V. W., & Yip, T. C. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0246 · Cited by 32
Self-citationLai, J. C., Yang, B., Lee, H. W., Lin, H., Tsochatzis, E. A., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M., Hagström, H., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-334981 · Cited by 32
Self-citationClinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease
Díaz, L. A., Thiele, M. S., Louvet, A., Lee, B. P., Ajmera, V. H., Tavaglione, F., Hsu, C. L., Huang, D. Q., Pose, E., Bataller, R. A., et al. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01120-5 · Cited by 33
Self-citationGraupera, I., Thiele, M. S., Castéra, L., Pera, G., Piano, S. S., Sòria, A., Fabrellas, N., Torán‐Monserrat, P., Chacón, C., Bech, K., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00354-5 · Cited by 33
Self-citationSung, S., Al‐Karaghouli, M., Tam, M., Wong, Y. J., Jayakumar, S., Davyduke, T., Ma, M. M., & Abraldeṣ, J. G. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000609 · Cited by 30
MASLD, MASH, and the CKM Spectrum
Zannad, F. M., Khan, M. S., Bansal, N., Böhm, M., Francque, S., Girerd, N., Januzzi, J. L., Miller, V., Piché, M., Ratziu, V., et al. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.12.015 · Cited by 33
Self-citationKanwal, F., Bril, F., Wong, V. W., Adams, L. A., Pfotenhauer, K. M., SKOLNIK, N., Wright, E. E., Eckel, R. H., Noureddin, M., Loomba, R. S., et al. (2026) · Gastroenterology · doi:10.1053/j.gastro.2026.01.047 · Cited by 37
Self-citationRinella, M. E., & Sookoian, S. C. (2026) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-026-01187-8 · Cited by 31
Petta, S., Kim, K., Targher, G., Romeo, S., Sookoian, S. C., Zheng, M., Aghemo, A., & Valenti, L. V. C. (2025) · Liver International · doi:10.1111/liv.70407 · Cited by 29
Self-citationFeng, G., Wong, V. W., Targher, G., Byrne, C. D., & Zheng, M. (2025) · Gut · doi:10.1136/gutjnl-2025-335542 · Cited by 28
Self-citationZhou, X., Chen, Q., Fan, Q. W., Kim, S. U., Yip, T. C., Petta, S., Nakajima, A., Tsochatzis, E. A., Boursier, J., Bugianesi, E., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001645 · Cited by 29
Self-citationMoving diagnosis of liver fibrosis into the community
Pose, E., Piano, S. S., Thiele, M. S., Fabrellas, N., Tsochatzis, E. A., & Ginès, P. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.01.026 · Cited by 24
Self-citationDisease classification, diagnostic challenges, and evolving clinical trial design in MASLD
Lauridsen, M. M., Ravnskjær, K., Gluud, L. L., & Sanyal, A. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci189953 · Cited by 29
Self-citationGogola, T., Pitkänen, S., Huovinen, M., Laitinen, H., & Küblbeck, J. (2025) · Environmental Research · doi:10.1016/j.envres.2025.121186 · Cited by 21
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis
Bhushan, S. R., Sohal, A., Noureddin, M., & Kowdley, K. V. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2478917 · Cited by 20
Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 23
Zargar, A. H., Bhansali, A. K., Majumder, A., Maheshwari, A., Bhattacharyya, A., Dasgupta, A., Saboo, B., Sethi, B. K., Sanyal, D., Seshadri, K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16496 · Cited by 25
John, B. V., Bastaich, D., Deng, Y., Singal, A. G., Dahman, B. A., & on behalf of the Veterans Analysis of Liver Disease (VALID) group of investigators (2025) · Hepatology · doi:10.1097/hep.0000000000001498 · Cited by 20
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study
Younossi, Z. M., de Avila, L., Petta, S., Hagström, H., Kim, S. U., Nakajima, A., Crespo, J., Castéra, L., Alkhouri, N., Zheng, M., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001564 · Cited by 20
Self-citationFeng, G., Mózes, F. E., Ji, D., Treeprasertsuk, S., Okanoue, T., Shima, T., Liang, H., Tsochatzis, E. A., Chen, J., Schattenberg, J. M., et al. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.045 · Cited by 20
Self-citationAssociation between longitudinal weight change and clinical outcome in individuals with MASLD
Shi, Y., Zhou, R., Kim, S. U., Yip, T. C., Tsochatzis, E. A., Petta, S., Nakajima, A., Hagström, H., Bugianesi, E., Chan, W., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001557 · Cited by 18
Self-citationGui, Z., Chen, X., Wang, D., Chen, Z., Liu, S. M., Yu, G., Jiang, Y., Duan, H., Pan, D.-Y., Xu, L., et al. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2486594 · Cited by 17
van Kleef, L. A., Strandberg, R., Pustjens, J., Hammar, N., Janssen, H. L. A., Hagström, H., & Brouwer, W. P. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.06.036 · Cited by 17
Self-citationHuang, L., Luo, Y., Zhang, L., Wu, M., & Hu, L. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-03850-x · Cited by 16
Neuschwander‐Tetri, B. A., Akbary, K., Carpenter, D. H., Noureddin, M., & Alkhouri, N. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.04.026 · Cited by 16
Is liver steatosis a disease or the emperor’s new clothes?
Krag, A. A., Tacke, F., Israelsen, M. E., & Younossi, Z. M. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2025.12.026 · Cited by 16
Younossi, Z. M., Kalligeros, M., Wong, V. W., Al-Naamani, K. M., Tacke, F., Tsochatzis, E. A., Crespo, J., El‐Kassas, M., Bril, F., Arrese, M. A., et al. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.03.030 · Cited by 16
Self-citationDetecting at-risk steatotic liver disease and liver fibrosis in the community
Adams, L. A., Thiele, M. S., & Tsochatzis, E. A. (2025) · Hepatology · doi:10.1097/hep.0000000000001400 · Cited by 14
Self-citationAceituno, L., Bañares, J., Pons, M., Rivera‐Esteban, J., Sabiote, C., Cammà, C., Ciancimino, G., Pennisi, G., Tulone, A., Ma, M. M., et al. (2025) · Gastroenterology · doi:10.1053/j.gastro.2025.08.020 · Cited by 16
Self-citationAjmera, V. H., Vuppalanchi, R., Khalili, M., Sheikh, M. Y., Risser, J. A., Klein, S., Tincopa, M. A., Madamba, E. V., Singh, S., Siddiqi, H., et al. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70516 · Cited by 15
A Pragmatic Management Approach for Metabolic Dysfunction-Associated Steatosis and Steatohepatitis
Shah, N., & Sanyal, A. J. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003215 · Cited by 15
Self-citationDukewich, M., Wilson, L. A., Dodge, J. L., Yuan, L., Hameed, B., Yates, K. P., Loomba, R. S., Neuschwander‐Tetri, B. A., Mack, W. J., & Terrault, N. A. (2026) · Journal of Hepatology · doi:10.1016/j.jhep.2026.02.002 · Cited by 13
Vutien, P., Giustini, A. B., Kim, N. J., Moon, A. M., Hsu, C., Mezzacappa, C., Borgerding, J. A., Johnson, K. M., VoPham, T., Berry, K., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001183 · Cited by 13
Allen, A. M., Lazarus, J. V., Alkhouri, N., Noureddin, M., Wong, V. W., Tsochatzis, E. A., de Avila, L., Racila, A., Nader, F., Mark, H. E., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000678 · Cited by 12
Self-citationTincopa, M. A., & Loomba, R. S. (2024) · Seminars in Liver Disease · doi:10.1055/s-0044-1788277 · Cited by 12
Allen, A. M., Arab, J. P., & Wong, V. W. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00990-5 · Cited by 13
Self-citationZhou, Z., Li, L., Wang, C., Li, S., Chen, P., Huang, J., & Peng, M. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1579453 · Cited by 11
Sanyal, A. J., Nakajima, A., Bugianesi, E., Sebastiani, G., Schattenberg, J. M., Adams, L. A., Noureddin, M., Yoneda, M., Bédossa, P., Younossi, Z. M., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.12.001 · Cited by 11
Self-citationEffects of polyphenols on non-alcoholic fatty liver disease: a case study of resveratrol
Zhao, Y., Ren, J., Chen, W., Gao, X., Yu, H., Li, X., Zheng, Y., & Yang, J. (2025) · Food & Function · doi:10.1039/d4fo04787g · Cited by 11
The importance of patient engagement in the multimodal treatment of MASLD
Boeckmans, J., Hagström, H., Cryer, D. R. H., & Schattenberg, J. M. (2025) · Communications Medicine · doi:10.1038/s43856-025-00871-1 · Cited by 16
Self-citationThe Liver in Diabetes and Metabolic Syndrome
Mahmoud, M. C., & Abdelmalek, M. F. (2025) · Clinics in Liver Disease · doi:10.1016/j.cld.2025.04.003 · Cited by 14
Shi, Y., Kim, S. U., Yip, T. C., Tsochatzis, E. A., Petta, S., Nakajima, A., Hagström, H., Bugianesi, E., Chan, W., Boursier, J., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.06.001 · Cited by 12
Self-citationNon-invasive assessment of liver fibrosis in MASLD: the need of sex-adjusted scores
Novielli, F., Matteis, C. D., Moschetta, A., & Crudele, L. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2557243 · Cited by 13
Concepción‐Zavaleta, M. J., Fuentes‐Mendoza, J. M., Yovera, J. G. G., Ruvalcaba-Barbosa, G. Y., Cura-Rodríguez, L. D., González-Rodríguez, J. S., Urteaga, L. A. C., Pérez-Reyes, A. I., Aldave, J. E. Q., & Paz‐Ibarra, J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i37.111435 · Cited by 11
Chen, Y., Dong, B., Jin, X., Liu, C., Zheng, M., Liang, X., Sun, Y., Lee, H. W., Lin, H., Tsochatzis, E. A., et al. (2026) · Gut · doi:10.1136/gutjnl-2025-337506 · Cited by 10
Self-citationMalandris, K., Katsoula, A., Liakos, A., Karagiannis, T., Sinakos, E., Γιουλεμέ, Ό., Klonizakis, P., Theocharidou, E., Gigi, E., Bekiari, E., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16142 · Cited by 11
Younossi, Z. M., Wong, V. W., Tsochatzis, E. A., Castéra, L., Betel, M., Henry, L. L., & Zelber‐Sagi, S. (2025) · Liver International · doi:10.1111/liv.70311 · Cited by 12
Self-citationLi, G., Wong, V. W., Chan, R., Sin, D. M.-C., Chu, C. W., Wong, V., Cheung, C., Lam, S., Lin, H., Yeung, S. S. Y., et al. (2025) · The Lancet HIV · doi:10.1016/s2352-3018(25)00032-3 · Cited by 10
Self-citationBianco, A., Bonfiglio, C., Franco, I., Bagnato, C. B., Verrelli, N., Stabile, D., & Shahini, E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217553 · Cited by 9
Liu, J., Yang, F., Gao, B., Yang, L., Cao, Y., & Zhou, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01574-w · Cited by 11
Predicting Liver-Related Outcomes in Steatotic Liver Disease
Younossi, Z. M. (2024) · JAMA · doi:10.1001/jama.2024.0799 · Cited by 9
Liu, S., Jiang, X., Fu, J., Zhong, V. W., Zhong, V. W., & Qi, X. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.07.005 · Cited by 8
Goyal, T., Song, M. W., Suresh, D., Jasty, V. S. J., Urias, E., Wijarnpreecha, K., Wong, Y. J., & Chen, V. L. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08683-4 · Cited by 7
Truong, E., Alnimer, L., GORNBEIN, J. A., Yang, J. D., Alkhouri, N., Harrison, S. A., & Noureddin, M. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-08850-1 · Cited by 9
Self-citationLong-term pioglitazone use in MASLD patients: insights from a multicentric preliminary study
Pereira, I. V. A., de Oliveira, A. B. S., Zitelli, P. M., Barbieri, L. A., Cardoso, A. C., Monteiro, M. J. D. S. D., de Oliveira, J. S., Stefano, J. T., Altikes, R. G., Reis, A. L. G., et al. (2025) · Clinics · doi:10.1016/j.clinsp.2025.100737 · Cited by 8
Woodard, J. S., Velji-Ibrahim, J., & Abrams, G. A. (2024) · Diseases · doi:10.3390/diseases12110288 · Cited by 8
Impact of first and further decompensation in patients with compensated ACLD due to MASLD
Pennisi, G., Maria, G. D., Wong, V. W., de Lédinghen, V., Sebastiani, G., Viganò, M., Fracanzani, A. L., Miele, L., Bugianesi, E., Ekstedt, M., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.014 · Cited by 8
Self-citationChun, H. S., Lee, M., Lee, H. A., Park, E. S., Choi, J. Y., Baek, H. S., Kim, T. H., Lin, H., Yip, T. C., Lee, H. W., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.06.025 · Cited by 9
Self-citationNdaa, M., Pandya, P., Swensson, J., Samala, N. R., Ajaz, S., Joshi, D., Ayoub, W. S., & Akisik, F. M. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.09.205 · Cited by 7
Austrian multisociety consensus on metabolic dysfunction-associated steatotic liver disease
Mandorfer, M., Semmler, G., Aigner, E. S., Bräuer, A., Brix, J. M., Clodi, M., Datz, C., Effenberger, M., Felsenreich, D. M., Ludvik, B. H., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02617-4 · Cited by 7
Fouad, Y., Elwakil, R., Sanai, F. M., Ojo, O. S., Awadhi, S. A., Ocama, P., Abdelkader, N. A., Al‐Busafi, S. A., Awuku, Y. A., Zaki, S., et al. (2026) · Annals of Hepatology · doi:10.1016/j.aohep.2026.102180 · Cited by 7
Schonfeld, E. A., Kierans, A. S., Fox, R. K., & Brandman, D. (2025) · Journal of the American College of Radiology · doi:10.1016/j.jacr.2024.12.014 · Cited by 7
Zhou, X., Yip, T. C., Huang, D. Q., Muthiah, M. D., Noureddin, M., & Zheng, M. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1131 · Cited by 7
Self-citationMa, H., Zhang, W., Zhao, Z., Jin, S., Li, L., Zong, R., Li, W., Zhang, Z., Cui, S., Pan, Y., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1604991 · Cited by 6
Sukocheva, O. A., Ow, T., Harding, D., Mire, M. L., & Tse, E. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.106675 · Cited by 6
Biomarkers in Metabolic Dysfunction-Associated Steatotic Liver Disease
De, A., Chalasani, N., & Duseja, A. K. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.09.003 · Cited by 6
Hu, S., Wang, D., Yu, Q., Chen, Z., Lu, W., Meng, Y., Peng, X., Liu, L., Wan, H., & Shen, J. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s569698 · Cited by 6
Metadata
- Authors
- Lin, H., Lee, H. W., Yip, T. C.-F., Tsochatzis, E., Petta, S., Bugianesi, E., Yoneda, M., Zheng, M.-H., Hagström, H., Boursier, J., Calleja, J. L., Goh, G. B.-B., Chan, W.-K., Gallego-Durán, R., Sanyal, A. J., de Lédinghen, V., Newsome, P. N., Fan, J.-G., Castéra, L., Lai, M., Harrison, S. A., Fournier-Poizat, C., Wong, G. L.-H., Pennisi, G., Armandi, A., Nakajima, A., Liu, W.-Y., Shang, Y., de Saint-Loup, M., Llop, E., Teh, K. K.-J., Lara-Romero, C., Asgharpour, A., Mahgoub, S., Chan, M. S.-W., Canivet, C. M., Romero-Gomez, M., Kim, S. U., Wong, V. W.-S., & VCTE-Prognosis Study Group
- Affiliations
- Chinese University of Hong Kong (HK)
- Yonsei University (KR)
- The Royal Free Hospital (GB)
- University of Palermo (IT)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Yokohama City University (JP)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Karolinska University Hospital (SE)
- Centre Hospitalier Universitaire d'Angers (FR)
- Department of Gastroenterology and Hepatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
- Singapore General Hospital (SG)
- University of Malaya (MY)
- Digestive Diseases Unit and CIBERehd, Virgen Del Rocío University Hospital, Seville, Spain
- Virginia Commonwealth University (US)
- Centre d’Investigation de la Fibrose Hépatique, Haut-Lévêque Hospital, University Hospital of Bordeaux, Pessac, France
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Shanghai Jiao Tong University (CN)
- Inserm (FR)
- Beth Israel Deaconess Medical Center (US)
- University of Oxford (GB)
- Echosens, Paris, France
- Karolinska Institutet (SE)
- Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, Angers, France
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Echosens (France) (FR)
- Corresponding author
- Kim, Seung Up
- Wong, Vincent Wai-Sun
- ORCID
- Lin, Huapeng
- Lee, Hye Won
- Yip, Terry Cheuk-Fung
- Tsochatzis, Emmanuel
- Petta, Salvatore
- Bugianesi, Elisabetta
- Yoneda, Masato
- Zheng, Ming-Hua
- Hagström, Hannes
- Boursier, Jérôme
- Goh, George Boon-Bee
- Chan, Wah-Kheong
- Sanyal, Arun J.
- Newsome, Philip N.
- Fan, Jian-Gao
- Castéra, Laurent
- Lai, Michelle
- Harrison, Stephen A.
- Wong, Grace Lai-Hung
- Pennisi, Grazia
- Armandi, Angelo
- Nakajima, Atsushi
- Liu, Wen-Yue
- Shang, Ying
- Llop, Elba
- Teh, Kevin Kim-Jun
- Asgharpour, Amon
- Kim, Seung Up
- Wong, Vincent Wai-Sun
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2024-04-16
- Volume
- 331
- Issue
- 15
- Pages
- 1287
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4393037494
- Cited by
- 250
- References
- 32
- Citations by year
- 2026: 106 · 2025: 98 · 2024: 46
- FWCI
- 76.29
- Type
- journal article
- Language
- en
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- Gilead Sciences
- Kowa Company
- Novo Nordisk
- Siemens Healthineers
- Japan Society for the Promotion of Science (21K08012)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- vibration-controlled transient elastography, non-alcoholic fatty liver disease, liver-related events, liver fibrosis, liver cirrhosis, noninvasive fibrosis assessment, outcome prediction, hepatic decompensation, hepatocellular carcinoma, liver transplantation, controlled attenuation parameter, hepatic steatosis, natural history (disease)
- MeSH terms
- Adolescent, Adult, Esophageal and Gastric Varices, Fatty Liver, Female, Gastrointestinal Hemorrhage, Carcinoma, Hepatocellular, Humans, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Vibration, Cohort Studies, Elasticity Imaging Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
